CONTACT
Other

Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study

PURPOSE: To assess the risk of gastrointestinal perforation, ulcers, or bleeding (PUB) associated with the use of conventional nonsteroidal anti-inflammatory drugs (NSAIDs) with proton pump inhibitors (PPIs) and selective COX-2 inhibitors, with orithout PPIs compared with conventional NSAIDs. METHODS: A case-control study was performed within conventional NSAIDs and/or selective COX-2 inhibitors users identified from the Dutch PHARMO Record Linkage System in the period 1998-2012

Read more
1 March 2017

Increased Antidepressant Drug Exposure in Psoriasis Patients: A Longitudinal Population-based Cohort Study

Psoriasis has a major impact on health-related quality of life. The present cohort study investigated the use of antidepressant drugs in psoriasis patients and a reference cohort, using pharmacy and hospitalization data from 1998 to 2008 for more tan 2.5 million Dutch residents. Multivariate Cox regression was used to compare the risk of first antidepressant use, and Poisson regression to compare the number of episodes of antidepressant use

Read more
1 September 2013

Increased use of antimicrobial agents and hospital admission for infections in patients with primary adrenal insufficiency: a cohort study

BACKGROUND: Previous studies have suggested that infections are an important cause of death in patients with Addison’s disease, but epidemiological studies on the frequency of infections in this population are lacking. OBJECTIVE: To assess and compre the incidence risk of infections in patients with primary adrenal insufficiency with controls

Read more
1 April 2013

Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The Netherlands

OBJECTIVE: To describe the use of gastroprotection (GP) among new chronic users of NSAIDs in the Netherlands by gastrointestinal (GI) risk factor (RF) score. METHODS: Data for this retrospective follow-up study were extracted from the PHARMO databae. We selected new chronic users of COX-2 inhibitors (coxibs) or traditional NSAIDs (tNSAIDs) between 1st January 2000 and 31st December 2004

Read more
1 January 2009

Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal

PURPOSE: To compare treatment changes after the rofecoxib withdrawal with changes occurring normally and to re-assess 12 months afterwards. METHODS: The PHARMO database comprised medication and hospital discharge records of over 3 million inhabitans in the Netherlands. The Study cohort included chronic coxib users with a coxib prescription on 30th September 2004; the Reference cohort others with a coxib prescription on 1st June 2004

Read more
1 January 2008

Filter by

Therapeutic area’s

Type of study